


Clinical study

Effectiveness of SagaPro™

From a parallel, randomized, double-blind, placebo-controlled clinical study on SagaPro, performed on men over the age of 45 suffering from lower urinary tract symptoms (LUTS) (N=69)

1. Increase in bladder volume

per nocturnal void for subgroup with less than 260 ml volume initially




Low bladder volume is directly related to urinary frequency.

The SagaPro group had an increase in bladder volume of 44.3 milliliters.

2. Reduction in nocturnal voids

for subgroup with more than 3 voids during standardized 8.7 hour night*




8 hours of sleep in the SagaPro group translates to an average of 1.44 fewer voids at night

A reduction in urinary frequency is important for proper sleep.

The SagaPro group experienced a significant reduction in voiding frequency.

3. Increase in duration of first sleep period

for subgroup 70 years or older and excluding those with sleep disorders



The first sleep period at night is generally regarded as the most important one.

The SagaPro group's uninterrupted first sleep period increased by an average of 101 minutes during the treatment.

The study also confirmed that SagaPro is a safe and well-tolerated treatment

* A "standard night" of 520 minutes was defined to harmonize different sleeping patterns.